Search | Clinical Trials Finder

Conditions: Heart Disease
Interventions: EPA 600, EPA 1800, Olive Oil, DHA; Dietary Supplement
Lead sponsor: Cardiovascular Research Associates; Network
Eligibility: 21 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Elevated Triglycerides, Cardiovascular Risk Factor
Interventions: DPA enriched n-3, n-3 control, Placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Renal Transplantation
Interventions: tacrolimus, CellCept, steroids (methylprednisone or prednisone); Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 29
States / cities: Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more

Conditions: Ischemic Stroke, Transient Ischemic Attack
Interventions: omega-3 polyunsaturated fatty acids (Lovaza); Dietary Supplement
Lead sponsor: Millard Fillmore Gates Hospital; Other
Eligibility: 25 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Placebo, RSV sF 20 mcg, MEDI7510 (20 mcg RSV sF), RSV sF 50 mcg, MEDI7510 (50 mcg RSV sF), RSV sF 80 mcg, MEDI7510 (80 mcg RSV sF); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 60 Years to 99 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Rockville, Maryland

Conditions: Absolute Uterine Infertility
Interventions: Uterine Transplant; Procedure
Lead sponsor: Baylor Research Institute; Other
Eligibility: 20 Years to 35 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 35 Years to 55 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: San Francisco, California • Newark, Delaware • Boston, Massachusetts + 4 more

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex; Drug · Procedure
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Total Parenteral Nutrition-Induced Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cognitive Benefits
Interventions: Citicoline, Omega-3 Fatty Acids and Creatine; Drug
Lead sponsor: Deborah Yurgelun-Todd; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: COVID-19
Interventions: Resveratrol, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: Marvin McCreary, MD; Other
Eligibility: 45 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions: Semaglutide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more

Conditions: Chronic Venous Leg Ulcers
Interventions: EPA+DHA, placebo; Dietary Supplement · Other
Lead sponsor: Ohio State University; Other
Eligibility: 55 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Methicillin Resistant Staphylococcus Aureus
Interventions: Decolonization; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 22,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Graft-versus-host Disease
Interventions: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Ruxolitinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 60 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Lupus Nephritis
Interventions: Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone, Placebo, Methylprednisolone; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 10 more

Conditions: Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, T-Cell Non-Hodgkin Lymphoma
Interventions: Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant, Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells, Total Nodal Irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Robert Lowsky; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions: Atorvastatin and Lisinopril, Placebo; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions: Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide; Drug · Procedure · Other + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Cellulitis
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Healthy
Interventions: DEPAKOTE® Tablets, 500 MG, DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Trigeminal Neuralgia
Interventions: Olive oil and Dietary Guideline recommendations, Dietary Guideline recommendations; Dietary Supplement · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy Volunteers
Interventions: M518101, M518101 Vehicle, sodium lauryl sulfate, saline; Drug · Other
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Search by objective public record fields.

Evaluation of the Safety and Biologic Effects of an Eicosapentaenoic (EPA)-Enriched Oil

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

Lovaza's Effect on Clopidogrel in a Neuro Population

A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility

Statins and Breast Cancer Biomarkers

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

Citicoline, Creatine, and Omega-3 Effects in Middle Age Women

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Impact of Omega-3 Fatty Acid Oral Therapy on Healing of Chronic Venous Leg Ulcers in Older Adults

Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

Fed Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets, 500 mg

Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia

Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers